1Cell.Ai

1Cell.Ai (formerly OneCell Diagnostics) develops AI-powered single-cell multi-omic analysis tools for precision oncology, combining cutting-edge molecular science with advanced AI technology to transform cancer diagnostics and care. The company's proprietary multi-omic cell biopsy platform combines circulating tumor cell (CTC) and ctDNA analysis, providing comprehensive insights into molecular alterations for personalized therapeutic decisions. Its product portfolio includes OncoIncytes, a live CTC and ctDNA investigation platform; 1Cell SOLO, an AI-driven single-cell isolation and analysis system for capturing and analyzing individual tumor cells; and 1Cell iCore, an integrated AI analytics platform for managing complex clinical trials and precision oncology studies. The technology leverages machine learning models trained on oncology-specific data, integrating genomic, transcriptomic, and proteomic data to reveal tumor heterogeneity and disease evolution. 1Cell.Ai serves clinicians and oncologists with non-invasive real-time molecular information, pharma and biopharma partners with multi-omics data for biomarker discovery and drug development, and researchers with tailored algorithms. The company presented seven research studies at AACR 2026 and is headquartered in Foster City, California. Founded in 2021, 1Cell.Ai has raised $16.0M in Series A funding from investors including Celesta Capital, Tenacity Ventures, Cedars Sinai, Eragon, and Singularity Venture Partners.